Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest

Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest
Treatment with Xtandi (enzalutamide) does not seem to improve overall survival in men with non-metastatic castration-resistant prostate cancer (CRPC), according to the first interim analysis of a Phase 3 clinical trial. These findings were published in the study, “Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer,” in the New England Journal of Medicine. Men with non-metastatic CRPC and rapidly rising prostate-specific

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *